1. Home
  2. SPOK vs ABEO Comparison

SPOK vs ABEO Comparison

Compare SPOK & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SPOK
  • ABEO
  • Stock Information
  • Founded
  • SPOK 2004
  • ABEO 1974
  • Country
  • SPOK United States
  • ABEO United States
  • Employees
  • SPOK N/A
  • ABEO N/A
  • Industry
  • SPOK Telecommunications Equipment
  • ABEO Biotechnology: Pharmaceutical Preparations
  • Sector
  • SPOK Telecommunications
  • ABEO Health Care
  • Exchange
  • SPOK Nasdaq
  • ABEO Nasdaq
  • Market Cap
  • SPOK 379.1M
  • ABEO 332.0M
  • IPO Year
  • SPOK 1992
  • ABEO 1980
  • Fundamental
  • Price
  • SPOK $18.04
  • ABEO $6.83
  • Analyst Decision
  • SPOK Hold
  • ABEO Strong Buy
  • Analyst Count
  • SPOK 1
  • ABEO 6
  • Target Price
  • SPOK $15.00
  • ABEO $18.17
  • AVG Volume (30 Days)
  • SPOK 168.1K
  • ABEO 695.3K
  • Earning Date
  • SPOK 07-30-2025
  • ABEO 08-14-2025
  • Dividend Yield
  • SPOK 6.98%
  • ABEO N/A
  • EPS Growth
  • SPOK 10.71
  • ABEO N/A
  • EPS
  • SPOK 0.83
  • ABEO 0.99
  • Revenue
  • SPOK $140,742,000.00
  • ABEO $400,000.00
  • Revenue This Year
  • SPOK $2.26
  • ABEO N/A
  • Revenue Next Year
  • SPOK $3.69
  • ABEO $339.63
  • P/E Ratio
  • SPOK $21.58
  • ABEO $6.91
  • Revenue Growth
  • SPOK 1.79
  • ABEO N/A
  • 52 Week Low
  • SPOK $13.55
  • ABEO $3.93
  • 52 Week High
  • SPOK $19.31
  • ABEO $7.54
  • Technical
  • Relative Strength Index (RSI)
  • SPOK 48.35
  • ABEO 52.71
  • Support Level
  • SPOK $17.61
  • ABEO $6.70
  • Resistance Level
  • SPOK $18.15
  • ABEO $7.15
  • Average True Range (ATR)
  • SPOK 0.33
  • ABEO 0.31
  • MACD
  • SPOK -0.08
  • ABEO -0.02
  • Stochastic Oscillator
  • SPOK 21.43
  • ABEO 46.62

About SPOK Spok Holdings Inc.

Spok Holdings Inc is a provider of healthcare communications. The company delivers clinical communication and collaboration solutions to help protect the health, well-being, and safety of people in the United States and abroad, on a limited basis, in Europe, Canada, Australia, Asia, and the Middle East. The company develops, sells, and supports enterprise-wide systems principally for healthcare and other organizations needing to automate, centralize, and standardize their approach to clinical and critical communications. The company offers its services and products to three market segments: healthcare, government, and large enterprise, with a greater emphasis on the healthcare market segment. Geographically, the company generates the majority of its revenue from the United States.

About ABEO Abeona Therapeutics Inc.

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.

Share on Social Networks: